Integration: Accelerating Biopharmaceutical Development by Achieving Speed, Cost and Quality without Compromise
Chairs: Brendan Hughes (Bristol Myers Squibb) and Gene Schaefer (J&J)
Historically, it has been accepted that speed, cost and quality cannot be achieved simultaneously, and that optimizing for one or another aspect inevitably comes at the expense of something else, “If you want it fast and cheap, don’t expect it to be very good”. This session seeks to address how these dimensions can be put together to reduce compromises among speed, cost and quality and across the lifecycle of product development and manufacturing. How the appropriate balance be achieved? How can the various technical disciplines be better integrated? How will improved business processes and regulatory paradigms contribute? Can truly revolutionary performance in terms of speed, cost and quality be achieved together? Potential topics would be expected to focus not exclusively on either speed, cost or quality but touch on multiple dimensions of improvement. Enabling tools and technologies that could have broad impact on speed, cost and quality would be of interest in this session as well.
Speakers
- Faster to Patient approach for significant benefit in cost, time, and product quality- Rohini Deshpande, Amgen
- A Process Development Strategy Providing Flexibility While Balancing Cost and Speed without Sacrificing Quality- Martin Allen, Pfizer
- Continuous Processing for Pre-Clinical and Clinical Manufacturing: Balancing Speed, Cost, and Quality- Jon Coffman, Boehringer Ingelheim
- Henrik Andersen, Bristol Myers Squibb
- Developing a leading open-access integrated biologics discovery, development and manufacturing platform to Expedite Global Development- Weichang Zhou, WuXi
- Scale-Down and Process Intensification: Two Key Opportunities for Integration and Cost Reduction- Gunter Jagschies, GE